1 / 4

Efficacy of Infliximab and Other Systemic Therapies in Psoriasis: Response Rates, PASI Scores, and DLQI Scores

This article presents response rates of patients with psoriasis treated with Infliximab and other systemic therapies, including PASI scores, DLQI scores, and rates of improvement. It also includes an algorithm for TB testing in European-based recommendations.

johnsonsarah
Download Presentation

Efficacy of Infliximab and Other Systemic Therapies in Psoriasis: Response Rates, PASI Scores, and DLQI Scores

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EXPRESS: Response Rates at Week 10 Per cent of patients with Physician’s Global Assessment of Cleared Per cent of patients with PASI Score of 0 (Clear) Per cent of patients with DLQI of 0 100 80 60 Per cent of patients 47.1 39.0 40 25.6 20 1.3 0.0 0.0 0 Infliximab 5 mg/kg (n=292) Infliximab 5 mg/kg (n=301) Infliximab 5 mg/kg (n=291) Placebo (n=77) Placebo (n=77) Placebo (n=77) Adapted from presentations during Dermatology Update 2006

  2. EXPRESS: Phase III 100 * * * 80.4% 82.2% * 80 * 60 Per cent of patients with 75% Improvement in PASI 40 20 0 0 2 6 10 14 22 24 Weeks Placebo (n=77) Infliximab 5 mg/kg (n=301) *P<0.001 vs. placebo Adapted from presentations during Dermatology Update 2006

  3. Efficacy of Systemic Therapies in Psoriasis PASI 75 or equivalent; induction therapy (10 to 16 weeks) 100% 100% 83% 80% 80% 80% 71% 68% 60% 60% 49% 60% 50% 34% 40% 27% 40% 21% 20% 20% 0% Alefacept i.m. 15 mg Efalizumab 1 mg/kg/wk 0% Etanercept 25 mg BIW Etanercept 50 mg BIW PUVA CyA UVB MTX FAE Infliximab 5 mg/kg Alefacept: Lebwohl et al. Arch Dermatol 2003 Efalizumab: Gordon et al. JAMA 2003 Menter et al. Arch Dermatol 2005 Etanercept: Leonardi et al. N Engl J Med 2003 Infliximab: Reich et al. Lancet 2005 PUVA, UVB: Spuls et al. Br J Dermatol 1997 CyA, MTX: Heydendael et al. N Engl J Med 2003 FAE: Altmeyer et al. J Am Acad Dermatol 1994 Adapted from presentations during Dermatology Update 2006

  4. Algorithm for TB Testing: European-based Recommendations New patient office visit Administer appropriate TB screening test (PPD skin test + CXR + family history) Evaluate test results Test negative PPD test positive and normal CXR PPD test positive and active TB Initiate latent TB treatment Treat active TB to resolution Initiate therapy Initiate therapy Initiate therapy Arend SM et al. Neth J Med 2003;61(4):111-9

More Related